EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED HODGKIN’S LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT

Código QR

EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED HODGKIN’S LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT

Objective: To identify the prognostic factors in relapsed Hodgkin’s Lymphoma patients with regards to their impact on the outcome of autologous hematopoietic stem cell transplant. Study Design: Retrospective observational study. Place and Duration of Study: Department of Medical Oncology, Shau...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jhanzeb Iftikhar, Hafiz Abubakar Sarwar, Fareeha Sheikh, Mohammad Iqbal Shah, Shafqual Ali Khan, Muhammad Abu Bakar, Neelam Siddiqui
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	autologous stem cell transplant hodgkin’s lymphoma Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a6666984a311421ea81f23ba7079fa44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

COMPLEX ESTIMATION OF BRONCHOPULMONARY SYSTEM IN PATIENTS WITH HODGKINS LYMPHOMA
por: Yu. N. Obgolts, et al.
Publicado: (2012)

Raoultella ornithinolytica in MALT-type non-Hodgkin Lymphoma
por: Rui Seixas, et al.
Publicado: (2021)

EPIDEMIOLOGY OF NON-HODGKIN’S LYMPHOMAS IN iRKUTSK REGION
por: E. V. Zubkova, et al.
Publicado: (2012)

Hodgkin's lymphoma
por: E. A. Demina, et al.
Publicado: (2020)

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
por: Lapuz C, et al.
Publicado: (2018)

Primary central nervous system Hodgkin Lymphoma: A case discussion and a hypothesis on the etiology
por: Ahmad Alfaseh, et al.
Publicado: (2019)

Analysis of mortality at non-Hodgkin lymphomas in the unit of cancer chemotherapy of Irkutsk Regional Oncologic Dispensary in 2011-2013
por: E. V. Zubkova, et al.
Publicado: (2014)

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo Luca, et al.
Publicado: (2021)

"RAPID AND SIMULTANEOUS DETERMINATION OF ADRIAMYCIN, BLEOMYCIN, VINBLASTINE AND DACARBAZINE IN PLASMA OF HODGKIN'S LYMPHOMA PATIENTS BY A REVERSED PHASE HPLC METHOD"
por: ZUBAIR MALIK,MUHAMMAD, et al.
Publicado: (2013)

Ocurrencia de leucemia mieloide crónica y linfoma no Hodgkin en un mismo paciente: Caso clínico
por: Morales F,Eugenia, et al.
Publicado: (1999)

Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic
por: Irina V. Poddubnaya, et al.
Publicado: (2020)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale MB, et al.
Publicado: (2017)

FEATURES OF THE CUMULATIVE INCIDENCE OF LYMPHOMAS IN DIFFERENT REGIONS OF THE CHERKASY REGION
por: V.V. Paramonov, et al.
Publicado: (2021)

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković B, et al.
Publicado: (2021)

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
por: Karantanos T, et al.
Publicado: (2017)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Artem Gusak, et al.
Publicado: (2021)

First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
por: Lali G. Babicheva, et al.
Publicado: (2020)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Fajun Pei, et al.
Publicado: (2021)

Unusual presentation of a clinically isolated temporal region mass: Non‐Hodgkin lymphoma
por: Mariam Mella, et al.
Publicado: (2021)

Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
por: Hongyan Ji, et al.
Publicado: (2021)

Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
por: Elena A. Demina
Publicado: (2021)

Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
por: Oliver,Carolina, et al.
Publicado: (2013)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai C, et al.
Publicado: (2019)

Massive pericardial effusion as the first manifestation of childhood non‐Hodgkin's lymphoma: A case report
por: Behzad Alizadeh, et al.
Publicado: (2021)

Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
por: Naif I. AlJohani, et al.
Publicado: (2021)

Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland – a report of the Polish Lymphoma Research Group
por: Ewa Kalinka, et al.
Publicado: (2019)

Oligoartritis, paniculitis y pioderma gangrenoso como manifestaciones de un Linfoma no Hodgkin
por: Erlij,Daniel, et al.
Publicado: (2018)

Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado
por: Díaz,Javier, et al.
Publicado: (2017)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells
por: Fabio Guolo, et al.
Publicado: (2021)

Role of PET/CT in initial evaluation of lymphoma patients
por: Manar Mohamed Naguib, et al.
Publicado: (2021)

A Validated HPLC-MS/MS Method for Quantification of Methotrexate and Application for Therapeutic Drug Monitoring in Children and Adults with Non-Hodgkin Lymphoma
por: Feng Z, et al.
Publicado: (2021)

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
por: Jiao Cai, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

A Case of Successful Treatment of Gram-Negative Sepsis Associated with Toxic Myelosuppression in a Patient with HIV-Associated Non-Hodgkin’s Lymphoma
por: D. D. Morikov, et al.
Publicado: (2021)

Compromiso pulmonar por linfoma no Hodgkin diseminado en un paciente con SIDA
por: Chernilo S,Sara, et al.
Publicado: (2001)

Evolución de un linfoma no Hodgkin “triple expresor” en un paciente trasplantado renal con quimioterapia DA-R-EPOCH. Caso clínico
por: Aránguiz,Natalia, et al.
Publicado: (2019)

Silent presentation of B-Cell Lymphoma in the mandible
por: H. Javed, et al.
Publicado: (2022)

Genetic Polymorphisms in NLRP3 Inflammasome-Associated Genes in Patients with B-Cell Non-Hodgkin’s Lymphoma
por: Liu ZH, et al.
Publicado: (2021)

Synchronous Hodgkin’s Lymphoma and Adenocarcinoma of the Lung with Metachronous Squamous Cell Carcinoma of Esophagus – A Rare Case Report
por: Aswin Nagarajan, et al.
Publicado: (2021)

Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
por: Ramírez V,Pablo, et al.
Publicado: (2006)